This consensus statement highlights how #CervicalCancer outcomes are shaped by #SocialDeterminantsOfHealth. Discussions include: the urgent need to expand #healthcareaccess, increase inclusive clinical trial enrollment, and address rurality & poverty in #cancerprevention.

Long-term oral contraceptive use as a risk factor for high-grade cervical lesions in women with high-risk #HPV 💊 https://t.co/HqJi4W0bKH @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4

#LeadArticle Checkpoint inhibitor rechallenge in advanced #endometrialcancer: revisiting the immune landscape beyond first-line therapy ✅ https://t.co/GPyvl3jeUf @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert

Some exciting news heading your way this week! #GynOnc #GynecologicOncology #GynecologicCancerAwareness #GynCancerAwareness #OncologyAwareness #ovariancancer #endometrialcancer #vuvlarcancer #cervicalcancer #vaginalcancer #CancerPrevention

Only 4 days to go until the global gynecologic oncology community gathers in Cape Town for #IGCS2025! Get ready for inspiring sessions, groundbreaking research, and meaningful connections with colleagues from around the world. 📅 November 5–7, 2025 📍 Cape Town, South Africa

🧬 New in #Pathology Archives! #Adenoid Basal Carcinoma of the #Cervix — rare #HPV-related low-grade tumor with p16+ basaloid nests & excellent prognosis. By Mohamed et al. 👉 https://t.co/98cHnDATCe @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety

Last minute submissions 🔥 #ESGO2026 Copenhagen 🇩🇰 Looking forward to reuniting with friends & mentors 🥳🥳 @ESGO_society @ENYGO_official @gyncsm @GynMe4 @OncoAlert @oncodaily @IJGConline @IJGCfellows @BirazbN21747

🎗️New in #IJGConline The #NOGGO-Expression X Study explores experiences & expectations of advance directives in #GynCancer patients 🇩🇪 📊 718 pts | 49% had a directive | 18% migration background 💬 76% wished doctors initiated conversations 🌍 Multilingual, culturally sensitive

🎙️ New #IJGCconversations! @pedroramirezMD chats with Dr. Rebecca Kristeleit on the #PEACOCC Trial — 💉 #Pembrolizumab in #ClearCellCancer 🧬 ✨ Insights into immune response & next steps for this rare histotype! 🎧 Listen now 👉 https://t.co/rGxGmWN7IX 🌍 @HsuMd @JayrajAarthi

#StandUpToCancer at Game 2 of World Series tonight @BlueJays vs. @Dodgers in T.O. 👏 @SGO_org @ASCO

🟢 #ICG fluorescence angiography may enhance surgical safety by guiding #bowel perfusion assessment during #OvarianCancer cytoreduction by @stephjeangill @thomasbartlMD @kfischermd @claritasantia @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen ✨

Management of intravenous #leiomyomatosis: a comprehensive review of surgical and perioperative considerations 🤕 Clinical Manifestations 🔍 Diagnosis 🔪 Treatment: Surgery 🩸 Anti-coagulation 💊 Post-operative considerations: Hormonal therapy as adjuvant treatment 📌

#EditorsChoice Addition of #metronidazole to standard-of-care perioperative prophylaxis at the time of hysterectomy for #gynecologicmalignancies @marina_frimer 💡 https://t.co/t00nLHipQo @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society

Phase II study evaluates #Palbociclib in recurrent #OvarianCancer 🧬 ➡️ Modest benefit: 10.5% ORR, PFS 3.3 mo ➡️ Promising benefit in low-grade serous ovarian cancer #LGSOC ➡️ Biomarkers identified: ✅ CDKN2A deletion – sensitivity ❌ RB1 deletion / CCNE1 amplification –

🎧 New #IJGCconversations episode! Dr. Pedro Ramirez @pedroramirezMD speaks with Michelle D. Lightfoot @mdslightfoot about #ADCs and strategies to prevent and manage #oralmucositis 👅 in #gynonc patients. 🔊 https://t.co/ERMkjjeloZ @HsuMd @JayrajAarthi @AndreFernandes2

Advanced epithelial #ovariancancer in older patients 📌 https://t.co/aPPZTFNooo @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro

Newly published 🔥🗞️: The ESGO Position Statement on promoting inclusive surgical ergonomics in #gynonc! Read it here 👉 https://t.co/NVixuhgSxM Highlights: ℹ️ Poorly designed instruments & operating theatre environments contribute to musculoskeletal injuries, fatigue, &

Excited to share this hot off the press paper 📄 focusing on applying principles of #ERAS from perspective of surgical trainees @BJSurgery @ErasSociety @ERAS_USA @UCalgaryMed https://t.co/cn1bPBjC05

Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant @SGO_org @IGCSociety @ESGO_society @ASCO @OncoAlert https://t.co/aC4dGGONpk

Optimizing the screening and management of preoperative anemia prior to gynecologic oncology surgery (OPRA1): A 🇨🇦 quality improvement initiative @SGO_org @IGCSociety @ESGO_society @ASCO @OncoAlert https://t.co/b11Q6XXBPZ